In a phase 1/2 study, the combination of the orally applied IDO inhibitor epacadostat with intravenous ipilimumab demonstrated clinical activity with objective response rates of 26% in immunotherapy-naïve melanoma patients [34]. The gene discussed is IDO1; the disease is melanoma.